

POSTERS PRESENTATIONS



Available on demand from
November 4, 2020 at 1:00 am
USA Eastern Standard Time

- **THEME 1**
Clinical trials: methodology P2 to LP03
- **THEME 2**
Clinical trials: results P16 to LP04
- **THEME 3**
Clinical trials: imaging P27 to LP07
- **THEME 4**
Clinical trials: biomarkers including plasma P40 to LP12
- **THEME 5**
Clinical trials: cognitive and functional endpoints P54 to P57
- **THEME 6**
Cognitive assessment and clinical trials P58 to LP13
- **THEME 8**
Health economics and clinical trials P69 to P72
- **THEME 9**
Epidemiology and clinical trials P74 to LP14
- **THEME 11**
New therapies and clinical trials P75 to P86
- **THEME 12**
Proof of concept/translational research in AD P88 to LP17
- **THEME 13**
Digital health/E-trials P96 to LP18
- **THEME 14**
Telemedicine and AD clinical trials P101

POSTER PRESENTATIONS

THEME 1

Clinical trials: methodology

- P2** Comparing the Down Syndrome Community Experience with Sporadic AD Participant Insights: Overcoming Barriers to Clinical Trial Recruitment
J. Hendrix 1, P. Ferrell 2, M. Chevrette 1, H. Barce 2, T. Batdorf 2, H. Hillerstrom 1
1Lumind Idsc - Burlington (United States), 2Eli Lilly & Company - Indianapolis (United States)
- P3** Key baseline characteristics of participants enrolled using tau PET screening in two phase 2 trials
S. Shcherbinin 1, S. Andersen 1, W. You 1, C. Evans 1, L. Munsie 1, A. Lo 1, J. Sims 1
Eli Lilly And Company - Indianapolis (United States)
- P4** First in Human study with ALZ-101, a unique and highly specific therapeutic vaccine against the neurotoxic oligomeric form of A β 1-42.
A. Sandberg 1, L. Nylander, 1, M. Sheinin 2, 3, J. Rinne 2, 4, 5, Z. Lovro' 2, K. Torfgård 1, A. Bylock 1
1Alzinova Ab - Gothenburg (Sweden), 2Crist - Turku (Finland), 3University of Turku, Institute of Biomedicine - Turku (Finland), 4Turku PET centre, University of Turku - Turku (Finland), 5Division of Clinical Neurosciences, Turku University Hospital - Turku (Finland)
- P5** Salvaging COVID-19 Interrupted Alzheimer Clinical Trials Using Virtual Patient Simulations
P. Van Der Graaf 1, H. Geerts 2
1Certara - Canterbury (United Kingdom), 2Certara - Berwyn (United States)
- P6** Predicting CDR-SB progression using data from 6 interventional clinical trials and ADNI
B. Toth 1, V. Steffen 1, Y. Chen 1, C. Rabe 1, M. Friesenhahn 1, T. Bittner 2
1Genentech - South San Francisco (United States), 2Roche - Basel (Switzerland)
- P7** Can Pharmacodynamic Interaction With Genotypes and Comedications Explain Variability In Clinical Trials? A Quantitative Systems Analysis
H. Geerts 1, A. Spiros 2
1Certara - Berwyn (United States), 2In Silico Biosciences - Portland (United States)
- P8** Finding treatment effects in Alzheimer's trials in the face of heterogeneity in disease progression
R. Jutten 1, S. Sikkens 1, W. Van Der Flier 1, P. Scheltens 1, P.J. Visser 1, B. Tijms 1
Amsterdam Umc, Location Vumc - Amsterdam (Netherlands)
- P9** Analytical validation of APTUS-A β assay: an accurate, reproducible and precise LC-MS/MS assay for quantifying plasma amyloid beta 40 and 42
K. Kirmess 1, M. Holubasch 1, S. Knapik 1, M. Meyer 1, J. Contois 1, Y. Hu 1, P. Verghese 1, E. Smith 1, S. Harpstrite 1, T. West 1, I. Fogelman 1, J. Braunstein 1, K. Yarasheski 1
C2n Diagnostics - St Louis (United States)
- P10** Reducing sample size requirements for randomized control trials using high-frequency markers
D. Taylor-Rodriguez 1, D. Lovitz 1, N. Mattek 2, C.Y. Wu 2, J. Kaye 2, H. Dodge 2, B. Jedynak 1
1Portland State University - Portland (United States), 2Ohsu - Portland (United States)
- P11** Disparities in Alzheimer's Disease Clinical Trial Enrollment in the United States and Canada: An Indigenous Perspective
N. Olson 1, B. Albensi 1
St Boniface Hospital Research - Winnipeg (Canada)
- P12** The Impact of Protocol Design on Data Quality Findings in Dementia Clinical Trials
D. Miller 1, X. Wang 1, A. Kott 2
1Signant Health - Blue Bell (United States), 2Signant Health - Prague (Czech Republic)
- P13** Recruitment and Retention in Two Decades of NIH-Funded Alzheimer's Disease Clinical Trials
M. Ritchie 1, 2, D. Gillen 3, 2, J. Grill 1, 4, 2
1Department Of Neurobiology And Behavior, University Of California, Irvine - Irvine (United States), 2Institute for Memory Impairments and Neurological Disorders, University of California, Irvine - Irvine (United States), 3Department Of Statistics, University Of California, Irvine - Irvine (United States), 4Department of Psychiatry & Human Behavior, University of California, Irvine - Irvine (United States)
- P14** Using Digital Twins to Decrease Enrollment and Increase Statistical Power in Alzheimer's Disease Clinical Trials
D. Hall 1, A. Schuler 1, Y. Pouliot 1, D. Bertolini 1, A. Smith 1, C. Fisher 1, J. Walsh 1
Unlearn.ai - San Francisco (United States)
- P15** Validation of a novel technology for non-invasive prognosis of amnesic MCI in clinics and clinical trials
K. Vejdani 1, E. Khosravi 1, T. Liebmann 1, P. Krishnamurthy 1, P. Kamali-Zare 1
1Darmiyan San Francisco (United States)
- LP01** Factors affecting willingness to participate in an FMT study for Alzheimer's disease
J. Thorstenson 1, M. Heston 1, 2, N. Vogt 1, S. Harding 1, M. Beilfuss 1, R. Aune 1, J. Langfus 3, N. Davenport-Sis 1, N. Chin 1, F. Rey 2, B. Bendlin 1, 4
1Wisconsin Alzheimer's Disease Research Center, University Of Wisconsin School Of Medicine And Public Health - Madison (United States), 2University Of Wisconsin-Madison (United States), 3Department Of Psychology And Neuroscience, University Of North Carolina At Chapel Hill - Chapel Hill (United States), 4Wisconsin Alzheimer's Institute, University of Wisconsin School of Medicine and Public Health - Madison (United States)

● POSTER PRESENTATIONS

LP02 Use of predictive algorithms for the selection of patients in clinical trials: an enrichment strategies comparison
A. Movschin 1, C. Longo Dos Santos 1, A. Mascia 1, J. Samper-González 1, U. Thoprakarn 1, P. Tran 1, 2, J.B. Martini 1, E. Cavedo 1
1Oynapse Sas - Paris (France), 2Equipe-projet ARAMIS, ICM, CNRS UMR 7225, Inserm U1117, Sorbonne Université UMR_S 1127, Centre Inria de Paris, Groupe Hospitalier Pitié-Salpêtrière Charles Foix, Faculté de Médecine Sorbonne Université - Paris (France)

LP03 Applying Feedback from an Advisory Board of Research Participants to Improve Clinical Trials in Alzheimer's Disease and Related Dementias
S. Walter 1
Alzheimer's Therapeutic Research Institute, University Of Southern California - San Diego, CA (United States)

THEME 2

Clinical trials: results

P16 New Horizons in Alzheimer Research from Amyloid and Beyond
J. Apter 1, R. Iqbal 2, O. Aung 2
1Global Clinical Trials - Princeton (United States), 2Princeton Medical Institute - Princeton (United States)

P17 Administering tricaprilin after a meal optimises bioavailability and minimises adverse events
J. Walker 1, L. Nelleman 1, L. Chow 1, B. Morimoto 2
1Cerecin - Singapore (Singapore), 2Cerecin - Denver (United States)

P18 Novel formulation AC-SD-03 of tricaprilin leads to excellent PK and safety in doses of up to 30g BID
L. Chow 1, L. Nelleman 1, B. Morimoto 2, J. Walker 1
1Cerecin - Singapore (Singapore), 2Cerecin - Denver (United States)

P19 An evidence-based risk-mitigation approach to study design in APOE4(-) mild to moderate AD
J. Walker 1, L. Nelleman 1, B. Morimoto 2, L. Chow 1
1Cerecin - Singapore (Singapore), 2Cerecin - Denver (United States)

P20 Tricaprilin Shows Similar PK, Safety and Tolerability in Caucasians and Asians
B. Morimoto 1, L. Nelleman 2, L. Chow 2, J. Walker 2
1Cerecin - Denver (United States), 2Cerecin - Singapore (Singapore)

P21 Frequency of Antipsychotic-Associated Adverse Events with Pimavanserin Treatment in Patients with Dementia-related Psychosis
G. Demos 1, E.P. Foff 1, D. Weintraub 2, B. Mcevoy 1, S. Stankovic 1
1ACADIA Pharmaceuticals, Inc. - Princeton (United States), 2University Of Pennsylvania School Of Medicine - Philadelphia (United States)

P22 The Alzheimer's disease THERapy with Neuroaid (ATHENE) Study: Assessing the Safety and Efficacy of Neuroaid II (MLC901) in patients with mild to moderate Alzheimer's disease stable on Cholinesterase inhibitors or Memantine: A 6-month Randomized, double-blind, placebo-controlled trial with a 6-month open label extension: RESULTS
C.L. Chen 1, B.Y. Tan 2, L. Qingshu 3, N. Venketasubramanian 4
1National University Of Singapore - Singapore (Singapore), 2St Luke's Hospital - Singapore (Singapore), 3Singapore Clinical Research Institute - Singapore (Singapore), 4Raffles Neuroscience Centre - Singapore (Singapore)

P23 A multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-phospho-tau antibody JNJ-63733657
W. Galpern 1, K. Haeverans 2, L. Janssens 2, G. Triana-Baltzer 3, H. Kolb 3, L. Li 1, P. Nandy 4, M. Mercken 2, K. Van Kolen 2, H. Sun 1, L. Van Nueten 2
1Janssen Research & Development - Titusville (United States), 2Janssen Research & Development - Beerse (Belgium), 3Janssen Research & Development - La Jolla (United States), 4Janssen Research & Development - Raritan (United States)

P24 The Critical Path for Alzheimer's Disease (CPAD) – Pre-competitive data sharing and generation of innovative high-impact quantitative tools to support Alzheimer's disease drug development
S. Sivakumaran 1, K. Romero 1, N. Hanan 1, Y. Karten 1, V. Sinha 2, S. Budd Haeberlein 3, N. Rabbee 4
1Critical Path Institute - Tucson (United States), 2Merck & Co. - Kenilworth (United States), 3Biogen - Cambridge (United States), 4Eisai - Woodcliff Lake (United States)

P25 Sensory Gamma Stimulation Therapy Reduces Sleep Disruptions in Alzheimer's Subjects as Assessed by Continuous Actigraphy Recordings
A. Cimenser 1, E. Hempel 1, T. Travers 1, M. Williams 1, M. Hajos 1, Z. Malchano 1
Cognito Therapeutics, Inc - Cambridge (United States)

LP04 Applying machine learning algorithms to predict amyloid risk in Japanese Trial-Ready Cohort webstudy
K. Sato 1, R. Ihara 2, K. Suzuki 3, Y. Niimi 4, A. Iwata 2, T. Iwatsubo 5
1Department Of Neurology, University Of Tokyo - Bunkyo City (Japan), 2Department Of Neurology, Tokyo Metropolitan Geriatric Medical Center Hospital - Itabashi City (Japan), 3Division Of Neurology, National Defence Medical College - Tokorozawa (Japan), 4Unit For Early And Exploratory Clinical Development, University Of Tokyo - Bunkyo City (Japan), 5Department Of Neuropathology, University Of Tokyo - Bunkyo City (Japan)

POSTER PRESENTATIONS

THEME 3

Clinical trials: imaging

- P27** **Molecular Imaging of Tau Pathology in Myotonic Dystrophy Type 1 and Alzheimer's disease: Implications for Underlying Mechanisms**
E. Poulin 1, C. Dallaire-Théroux 2, 3, A.M. Cayer 2, 1, D. Bédard-Tremblay 2, 1, T. Rouleau-Bonenfant 2, 1, F. St-Onge 4, J.M. Beaugregard 5, N. Sergeant 6, J. Puymirat 5, R. Jr. Laforce 2, 3, 1
1Clinique Interdisciplinaire De Mémoire, Département Des Sciences Neurologiques, CHU de Québec - Québec (Canada), 2Université Laval, Faculté De Médecine - Québec (Canada), 3Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques, CHU de Québec - Québec (Canada), 4Douglas Health Institute - Montréal (Canada), 5Centre De Recherche du CHU de Québec - Québec (Canada), 6Université De Lille, CHRU, Inserm, UMRS 1172, Equipe Alzheimer & Tauopathies - Lille (France)
- P28** **A Multi-input, Multi-modal Deep Learning Model to Predict Time to Conversion to Alzheimer's Disease**
D. Hibar 1, B. Toth 1, C. Rabe 1, D. Clayton 1
Genentech, Inc - South San Francisco (United States)
- P29** **Perceptions of Amyloid Imaging Among Cognitively Normal Older Adults with Elevated and Not Elevated Amyloid**
M. Ryan 1, 2, D. Gillen 1, 2, J. Grill 1, 3, 4
1Institute For Memory Impairments And Neurological Disorders, University Of California, Irvine - Irvine (United States), 2Department Of Statistics, University Of California, Irvine - Irvine (United States), 3Department of Psychiatry and Human Behavior, University of California, Irvine - Irvine (United States), 4Department of Neurobiology and Behavior, University of California, Irvine - Irvine (United States)
- P30** **Neuroimaging results of the AMBAR Study, a randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease**
G. Cuberas-Borrós 1, E. Franquet 2, I. Roca 2, J. Castell-Conesa 2, L. Nuñez 3, M. Boada 4, 5, O.L. López 6, C. Grifols 3, M. Barceló 3, A. Páez 3
1Research & Innovation Unit, Althaia Xarxa Assistencial Universitària De Manresa - Manresa (Spain), 2Department Of Nuclear Medicine, Hospital Universitari Vall D'hebrón, Universitat Autònoma De Barcelona - Barcelona (Spain), 3Alzheimer's Research Group, Grifols - Barcelona (Spain), 4Research Center And Memory Clinic, Fundació Ace, Institut Català De Neurociències Aplicades-Universitat Internacional De Catalunya - Barcelona (Spain), 5Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, - Madrid (Spain), 6Departments Of Neurology And Psychiatry, University Of Pittsburgh School Of Medicine - Pittsburgh, Pennsylvania (United States)
- P31** **Greater sleep disturbance is associated with lower myelin content in the cingulum in a cohort enriched for Alzheimer's disease risk**
K.L. Yang 1, D.C. Dean 2, 3, 4, J.M. Oh 1, N. Davenport-Sis 1, D.T. Plante 5, B.A. Riedner 5, S. Asthana 1, 6, 7, S.C. Johnson 1, 6, 7, A. Alexander 3, 4, B.B. Bendlin 1, 6, 7
1Wisconsin Alzheimer's Disease Research Center, University Of Wisconsin - Madison (United States), 2Department Of Pediatrics, University Of Wisconsin - Madison (United States), 3Department Of Medical Physics, University Of Wisconsin - Madison (United States), 4Waisman Center, University of Wisconsin - Madison (United States), 5Wisconsin Institute For Sleep And Consciousness, University Of Wisconsin - Madison (United States), 6Wisconsin Alzheimer's Institute, University Of Wisconsin - Madison (United States), 7Geriatric Research Education and Clinical Center, William S. Middleton Veterans Hospital - Madison (United States)
- P32** **Cerebellar atrophy can predict conversion of amnesic mild cognitive impairment to dementia in patient with amyloid negative**
H.J. Kim 1, S. Lee 1, S. Jo 1, J.H. Lee 1
Department Of Neurology, Asan Medical Center - Seoul (Korea, Republic of)
- P33** **Early impairment in the ventral visual pathway can predict conversion to dementia in patients with amyloid-negative amnesic mild cognitive impairment**
H.J. Kim 1, E.N. Cheong 2, S. Jo 1, S. Lee 1, W.H. Shim 3, J.H. Lee 1
1Department Of Neurology, Asan Medical Center, University Of Ulsan College Of Medicine - Songpa-Gu, Seoul (Korea, Republic of), 2Department Of Medical Science And Asan Medical Institute Of Convergence Science And Technology, Asan Medical Center, University Of Ulsan College Of Medicine - Songpa-Gu, Seoul (Korea, Republic of), 3Health Innovation Big Data Center, Asan Institute For Life Sciences, Department Of Radiology And Research Institute Of Radiology, Asan Medical Center, University Of Ulsan College Of Medicine - Songpa-Gu, Seoul (Korea, Republic of)
- P34** **Prognosis of mild cognitive impairment of uncertain etiology: Assessment and analysis of concordant cases from the IDEAS study**
D. Weidman 1, V. Ghisays 1, H. Protas 1, Y. Chen 1, V. Devadas 1, G. Sidarous 1, Y. Su 1
Banner Alzheimer's Institute - Phoenix (United States)
- P35** **The effect of cerebral amyloid angiopathy on regional cortical atrophy, independent of cortical amyloid pathology**
S. Jo 1, E.N. Cheong 1, H.J. Kim 1, S.J. Lee 1, J.H. Lee 1
Asan Medical Center - Seoul (Korea, Republic of)

POSTER PRESENTATIONS

- P37** **Effect of multidomain interventions on brain functional connectivity of elderly people with spontaneous memory complaint**
L. Perus 1, 2, 3, E. Le Bars 4, J. Deverdun 5, J.F. Mangin 6, A. Gabelle 1
1Memory Resources and Research Center, Montpellier University Hospital, 34 295 Montpellier and Inserm U1061 and University Of Montpellier I-Site Muse - Montpellier (France), 2Institut d'Imagerie Fonctionnelle Humaine, I2FH, Montpellier University Hospital, Montpellier, France. - Montpellier (France), 3Neurospin, CEA, Gif-sur-Yvette, France - Saclay (France), 4Institut D'imagerie Fonctionnelle Humaine, I2fh, Neuroradiology Department, Montpellier University Hospital, Montpellier, France. - Montpellier (France), 5Institut D'imagerie Fonctionnelle Humaine, I2fh, Montpellier University Hospital, Montpellier, France. - Montpellier (France), 6Neurospin, CEA - Gif-Sur-Yvette (France)
- LP05** **Regional Retinal Amyloid Imaging in a Cohort of Patients with Mild Cognitive Impairment**
M. Koronyo-Hamaoui 1, 2, T. Torbati 1, 3, J. Sheyn 1, P.D. Lyden 4, A. Sherzai 5, D. Sherzai 5, D. Sherman 6, S. Frautschy 7, 8, A.D. Czeszynski 9, S. Verdooner 9, K.L. Black 1, Y. Koronyo 1, O. Dumitrascu 4
1Department Of Neurosurgery, Maxine Dunitz Neurosurgical Institute, Cedars-Sinai Medical Center- Los Angeles (United States), 2Department of Biomedical Sciences, Cedars-Sinai Medical Center- Los Angeles (United States), 3Western University Of Health Sciences, College Of Osteopathic Medicine Of The Pacific- Pomona (United States), 4Department Of Neurology, Cedars-Sinai Medical Center- Los Angeles (United States), 5Department Of Neurology, Loma Linda University- Loma Linda (United States), 6Department Of Neuropsychology, Cedars-Sinai Medical Center- Los Angeles (United States), 7Department Of Neurology, University Of California, Los Angeles - Los Angeles (United States), 8Geriatric Research Education and Clinical Center, Veterans Administration- Los Angeles (United States), 9Neurovision Imaging Inc.- Sacramento (United States)
- LP06** **The effects of home-based, robot cognitive intervention on the functional brain network in patients with mild cognitive impairment**
G.H. Kim 1, B.R. Kim 1, K. Yoo 2, M.Y. Chun 1, K.D. Park 1, J. Jee Hyang 3
1Ewha Womans University Mokdong Hospital - Seoul (Korea, Republic of), 2Department Of Psychology Yale University - New Haven, Ct (United States), 3Ewha Womans University Seoul Hospital - Seoul (Korea, Republic of)
- LP07** **Update on Ideas and New Ideas Studies**
G.D. Rabinovici 1, 2, C. Gatsonis 3, C. Appgar 4, P. Dilworth-Anderson 5, I. Gareen 6, L. Hanna 6, C.V. Hill 7, B.E. Hillner 8, S. Hoover 9, A. March 4, S. O'bryant 10, R.A. Rissman 11, M. Rodriguez 12, K.S. Smith 13, Y. Song 14, R.A. Whitmer 15, C.H. Wilkins 16, C. Windon 13, B.A. Siegel 17, M.C. Carrillo 7
1Depts. Of Neurology, Ucsf - San Francisco (United States), 2Department Of Radiology & Biomedical Imaging, , University Of California San Francisco - San Francisco (United States), 3Dept Of Biostatistics And Center For Statistical Sciences, Brown University - Providence (United States), 4American College Of Radiology - Philadelphia (United States), 5Gillings School Of Global Public Health & Center For Health Equity Research, University Of North Carolina-Chapel Hill - Chapel Hill (United States), 6Center For Statistical Sciences & Department Of Epidemiology, Brown University School Of Public Health - Providence (United States), 7Alzheimer's Association - Chicago (United States), 8Department Of Medicine, Virginia Commonwealth University - Richmond (United States), 9Center For Health Equity Research, University Of North Carolina-Chapel Hill - Chapel Hill (United States), 10Institute For Translational Research, University Of North Texas Health Science Center - Philadelphia (United States), 11Department Of Neurosciences, Ucsd & Alzheimer's Therapeutic Research Institute, Usc - San Diego (United States), 12Department Of Medicine, Vanderbilt University School Of Medicine - Nashville (United States), 13Dept. Of Neurology, Ucsf - San Francisco (United States), 14Center For Statistical Science, Brown University School Of Public Health - Providence (United States), 15Department Of Public Health Sciences, Uc Davis - Davis (United States), 16Department Of Medicine, Vanderbilt University School Of Medicine & Department Of Medicine, Meharry Medical College - Nashville (United States), 17Dept. Of Radiology, Washington University - St. Louis (United States)

THEME 4

Clinical trials: biomarkers including plasma

- P40** **Bio-Hermes: A Biomarker Study Initiated By The Global Alzheimer's Platform Foundation® To Compare Select Digital and Blood-Based Biomarkers With Clinical Diagnosis and Amyloid- β PET Images**
J. Dwyer 1, S. Walsh 1, D. Beaugregard 1, E. Gorman 1, J. Bork 1, K. Smith 1, S. Hollingshead 1, R. Mohs 1
Global Alzheimer's Platform Foundation - Washington (United States)
- P41** **Down Syndrome Associated Alzheimer's Disease: Early Data from the Longitudinal Investigation for Enhancing Down Syndrome Research (LIFE-DSR) Study**
J. Hendrix 1, H. Hillerstrom 1, D. Airey 2, A. Britton 1, R. Chavez 3, J. Dage 2, K. Faber 4, T. Foroud 4, D. Ladesma 3, C. Revta 3, K. Schafer 3, K. Wilmes 4, J. Zimmer 2, H. Feldman 3, W. Mobley 5
1Lumind Idsc - Burlington (United States), 2Eli Lilly And Co. - Indianapolis (United States), 3Department of Neurosciences, Alzheimer's Disease Cooperative Study, University of California San Diego - San Diego (United States), 4National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD), Indiana University School of Medicine - Indianapolis (United States), 5Department of Neurosciences, University of California, San Diego - San Diego (United States)
- P42** **Studies on the Practical Performance of a Plasma Amyloid β Measurement System by Immunoprecipitation Combined with MALDI-TOF Mass Spectrometry**
N. Kaneko 1, Y. Hioki 1, 2, R. Yoda 1, A. Korenaga 1, Y. Ohashi 3, M. Honda 3, S. Sekiya 1, S. Iwamoto 1, K. Tsujino 3, K. Tanaka 1
1Koichi Tanaka Mass Spectrometry Research Laboratory, Shimadzu Corporation - Kyoto (Japan), 2Shimadzu Scientific Instruments - Frederick, Md (United States), 3Shimadzu Techno-Research - Kyoto (Japan)
- P43** **Identification of ADAMT5 as an Amyloid Precursor Protein Cleaving Enzyme at 669 Site in APP669-711 Production Pathway**
T. Tomita 1, M. Matsuzaki 1, N. Kaneko 2, M. Yokoyama 1, Y. Yoshizawa 1, Y. Hioki 2, 3, S. Iwamoto 2, K. Tanaka 2
1Laboratory of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Sciences, The University Of Tokyo - Tokyo (Japan), 2Koichi Tanaka Mass Spectrometry Research Laboratory, Shimadzu Corporation - Kyoto (Japan), 3Shimadzu Scientific Instruments - Frederick, MD (United States)

● POSTER PRESENTATIONS

- P44** Identification of prognostic protein biomarkers for cognitive dysfunction in the Origin trial
S. Hess 1
Sanofi - Frankfurt (Germany)
- P45** Deep Proteomic Profiling of AD CSF for Unbiased Biomarker Discovery and Subject Stratification
Y. Feng 1, R. Bruderer 1, D. Heinzmann 1, L. Reiter 1
Biognosys - Schlieren (Switzerland)
- P46** Antibody free, Mass Spectrometric procedure for the determination of A β 40 and A β 42 in human plasma
L. Sarasa 1, P. Pesini 1, M. Sarasa 1, J.A. Allué 1
Araclon Biotech - Zaragoza (Spain)
- P47** Cholesterol and triglyceride levels in Alzheimer's disease patients undergoing therapeutic plasma exchange with albumin replacement
A.M. Ortiz 1, C. Minguet 1, L. Nuñez 1, A. Ruiz 2, 3, O.L. Lopez 4, M. Boada 2, 3, A. Páez 1, M. Costa 1
1Alzheimer's Research Group, Grifols - Barcelona (Spain), 2Research Center and Memory Clinic, Fundació Ace, Institut Català De Neurociències Aplicades-Universitat Internacional De Catalunya - Barcelona (Spain), 3Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III - Madrid (Spain), 4Departments of Neurology and Psychiatry, University of Pittsburgh School of Medicine - Pittsburgh, Pennsylvania (United States)
- P48** PK/PD model of the effects of the anti-Sortilin antibody ALO01 in humans
M. Ward 1, R. Paul 1, F. Yeh 1, H. Long 1, O. Siddiqui 1, M. Hagey 1, I. Siah 1, T. Schwabe 1, S. Kathman 2, C. Hines 2
1Alector - South San Francisco, CA (United States), 2PPD - Wilmington, NC (United States)
- P49** Platelet-miRNAs as biomarkers for dementia with Lewy bodies
A. Gamez-Valero 1, D. Vilas 2, L. Ispuerto 2, F. Borrás 1, R. Alvarez 1, K. Beyer 1
1Research Institute Germans Trias I Pujol (Spain), 2University Hospital Germans Trias I Pujol (Spain)
- P50** Elecsys CSF assays accurately distinguish AD from frontotemporal lobar degeneration
M. Ortner 1, O. Goldhardt 1, J.P. Weinberger 2, F. Müller-Sarnowski 1, J. Diehl-Schmid 1, H. Förstl 1, I. Yakushev 3, T. Grimmer 1
1Department of Psychiatry and Psychotherapy, Klinikum Rechts Der Isar, Technical University of Munich, School of Medicine - Munich (Germany), 2Roche Diagnostics GmbH - Penzberg (Germany), 3Department of Nuclear Medicine, Klinikum Rechts Der Isar, Technical University of Munich - Munich (Germany)
- P51** Using cortical diffusivity analysis to predict progression in early Alzheimer's Disease
M. Torso 1, I. Hardingham 1, M. Jenkinson 2, S. Chance 1
1Oxford Brain Diagnostics - Oxford (United Kingdom), 2University of Oxford - Oxford (United Kingdom)
- P52** Level of neurodegeneration-inducing memory CD8 T cells predicts Alzheimer's disease and Alzheimer's-related MCI, and correlates with cognitive decline in banked blood samples from multiple cohorts
C. Wheeler 1, D. Van Dam 2, Y. Vermeiren 2, H. De Reu 2, V. Van Tendeloo 2, P.P. De Deyn 3, K. Trujillo 1
1TNeuro Pharma, Inc. - Albuquerque (United States), 2University of Antwerp - Antwerp (Belgium), 3University of Antwerp, University Center Groningen - Groningen (Netherlands)
- P53** Transcranial Electromagnetic Treatment (TENT) Normalizes Plasma Cytokine Levels in Alzheimer's Patients: Both Immediate and Long-term Immunoregulation
H. Abulaban 1, R. Baranowski 2, X. Lin 3, E. Goodwin 4, B. Gordon 4, A. Gary 4, C. Cao 3
1Axiom Clinical Research of Florida - Tampa (United States), 2Left Coast Engineering - Escondido (United States), 3University of South Florida Taneja College of Pharmacy - Tampa (United States), 4Neuroem Therapeutics, Inc - Phoenix (United States)
- LP08** The analytical assessment of three research Simoa assays for plasma measurement of phosphorylated tau (pT181, pT217, pT231)
Jeroen Vanbrabant (1), Erik Stoops (1), Kaj Blennow (2,3), Eugene Vanmechelen (1)
(1) Adx Neurosciences Nv, Belgium, (2) Department Of Psychiatry And Neurochemistry, The Sahlgrenska Academy At The University Of Gothenburg, Sweden, (3) Clinical Neurochemistry Laboratory, Sweden
- LP09** Blood-based Detection of Early-stage Alzheimer's Using Multiomics and Machine Learning
B. Souchet 1, A. Michail 1, B. Billoir 1, F. Mouton-Ligier 2, 3, 4, J. Fortea 5, 6, 7, A. Lleó 6, 7, C. Paquet 2, 3, 4, J. Braudeau 1
1Agent - Paris (France), 2Université De Paris - Paris (France), 3Centre de Neurologie Cognitive Hopital LARIBOISIÈRE Paris APHP - Paris (France), 4INSERM U1144 - Paris (France), 5Barcelona Down Medical Center, Fundació Catalana De Síndrome De Down - Barcelona (Spain), 6Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona - Barcelona (Spain), 7Center of Biomedical Investigation Network for Neurodegenerative Diseases - Madrid (Spain)
- LP10** Plasma A β ratio measured on a fully automated immunoassay predicts amyloid positivity defined by amyloid PET centiloid
K. Yamashita 1, S. Watanabe 1, K. Matsumoto 1, M. Miura 1, T. Iino 1, T. Watanabe 2, S. Iwanaga 1, D. Verbel 3, M. Kanekiyo 3, S. Dhadda 3, M. Ino 4, A. Koyama 3, T. Yoshida 1
1Sysmex Corporation - Kobe (Japan), 2Sysmex R&d Center Americas, Inc. - Mundelein (United States), 3Eisai Inc. - Woodcliff Lake (United States), 4Eisai Co., Ltd. - Tsukuba (Japan)

● POSTER PRESENTATIONS

- LP11** Biomarkers of response to nabilone in agitated patients with moderate-to-severe Alzheimer's disease patients
M. Ruthirakuhan 1, N. Herrmann 1, A.C. Andreatza 2, N.P.L.G. Verhoeff 3, D. Gallagher 1, S.E. Black 1, K.L. Lancot 1
1Sunnybrook Research Institute - Toronto (Canada), 2University Of Toronto - Toronto (Canada), 3Baycrest Health Sciences - Toronto (Canada)
- LP12** Pre-Analytical Effects of Cap Contact, Temperature, and Mixing on CSF A β 1-42 Concentrations when Measured on an Automated Chemiluminescent Platform
J. Darrow 1, R. Esquivel 2, S. Gannon 2, A. Calabro 2, J. Lantham 2, A. Orusakwe 2, N. Benina 2, A. Rao 1, S. Gulyani 1, K. Khingelova 1, K. Bandeen-Roche 1, M. Albert 1, A. Kapoor 1, A. Moghekar 1
1Johns Hopkins - Baltimore (United States), 2Fujirebio Diagnostics, Inc. - Malvern (United States)

THEME 5

Clinical trials: cognitive and functional endpoints

- P54** The effect of multi-tasking exercise intervention on cognitive function in elderly and cognitive impairment patients: a pilot multicenter study
K.W. Park 1, H.J. Lee 2, H. Park 3
1Dong-A University College of Medicine - Busan (Korea, Republic of), 2Busan Metropolitan Dementia Center - Busan (Korea, Republic of), 3Dong-A University - Busan (Korea, Republic of)
- P56** Exercise and carbohydrate-restricted diet associates with improved insulin resistance and cognitive performance
M.B. Heston 1, 2, J.M. Gaitan 1, Y. Ma 1, B. Derynda 3, S. Lose 1, M.P. Kozuch 1, 4, O.C. Okonkwo 1, K.A. Gretebeck 5, 6, R.J. Gretebeck 5, 7, B.B. Bendlin 1
1Wisconsin Alzheimer's Disease Research Center, University Of Wisconsin School Of Medicine And Public Health - Madison (United States), 2Cellular and Molecular Pathology, University of Wisconsin-Madison - Madison (United States), 3Nova Southeastern University - Madison (United States), 4Rollins School of Public Health, Emory University - Atlanta (United States), 5College Of Nursing, Marquette University - Milwaukee (United States), 6School of Nursing, University of Wisconsin-Madison - Madison (United States), 7Department of Exercise and Sport Science, University of Wisconsin-La Crosse - La Crosse (United States)
- P57** Real-time capture of gait and actigraphy using industry-grade wearable devices in older adults with and without subjective cognitive decline: Preliminary compliance, sensitivity, and correlations with cognition
A. Atkins 1, W. Horan 1, M. Kraus 1, J. Linthicum 1, R. Keefe 1
Verasci - Durham, NC (United States)

THEME 6

Cognitive assessment and clinical trials

- P58** Using speech measures as prognostic markers of rapid cognitive decline: Applications to clinical trial enrichment
K. Mueller 1, R. Kosciak 1, S. Hahn 2, G. Stegmann 2, J. Liss 2, V. Berisha 2
1University of Wisconsin-Madison - Madison, WI (United States), 2Arizona State University - Tempe, AZ (United States)
- P59** Generation of an optimized neuropsychological feature set for the quick screening of mild cognitive impairment in clinical settings
M.J. Kleiman 1, J. Galvin 1
University of Miami Miller School Of Medicine - Miami, FL (United States)
- P60** Congruence of clinical assessment instruments with online narratives over social media by patients with Alzheimer's disease and caregivers
A. Tahami 1, Y. Stern 2, S. Doogan 3, Q. Zhang 1
1Eisai, Inc. - Woodcliff Lake (United States), 2Columbia University - New York (United States), 3Real Life Sciences, Inc. - New York (United States)
- P61** Remote assessment of speech and language changes in Primary Progressive Aphasia (PPA) and behavioral variant FTD
J. Robin 1, M. Xu 1, L. Kaufman 1, M. Hagey 2, R. Paul 2, O. Siddiqui 2, M. Ward 2, W. Simpson 1, 3
1Winterlight Labs - Toronto (Canada), 2Alector, Inc. - South San Francisco, CA (United States), 3McMaster University - Hamilton (Canada)
- P63** Cognitive Profiles of Common Neurological Co-morbidities: A Review of Systematic Reviews
C. Ganzer 1, A. Seifan 2
1Hunter College School of Nursing - New York, NY (United States), 2The Neuro Well Free Corporation - Miami Beach, FL (United States)

POSTER PRESENTATIONS

- P64** **Insulin resistance and longitudinal cognition in middle-aged and older adults**
G. Ennis 1, E. Jonaitis 1, R. Kosciak 1, L. Clark 1, S. Bouges 1, T. James 1, N. Chin 1, C. Engelman 1, R. Anderson 1, S. Asthana 1, S. Johnson 1, B. Bendlin 1
University of Wisconsin-Madison - Madison, WI (United States)
- P65** **Polygenic Risk for Alzheimer's Disease Predicts MMSE Decline in Amyloid Positive Older Adults**
A. Moore 1, J. Cara 1, L. Schneider 2, A. Torkamani 3, C. Cruchaga 4, J. Collens 1
1Vivid Genomics - San Diego, CA (United States), 2Departments Of Neurology, Psychiatry and Behavioral Sciences, Keck School Of Medicine, University Of Southern California - Los Angeles, CA (United States), 3Scripps Research Translational Institute - La Jolla, CA (United States), 4Knight Alzheimer's Disease Research Center, Washington University School Of Medicine - St. Louis, MI (United States)
- P66** **Toward Discriminating Alzheimer's Disease from Other Dementing Disorders with Modeled Cognitive Processes**
J.R. Bock 1, M.D. Lee 2, W.R. Shankle 1, 2, 3, J. Hara 1, 3, D. Fortier 1, T. Mangrola 1
1Medical Care Corporation - Newport Beach, CA (United States), 2Dept. Of Cognitive Sciences, University of California At Irvine - Irvine, CA (United States), 3Pickup Family Neuroscience Institute, Hoag Memorial Hospital - Newport Beach, CA (United States)
- P67** **Clinical correlates of types of memory complaints in subjective cognitive decline and amnesic mild cognitive impairment**
S.Y. Ryu 1, S.B. Lee 1, T.J. Lee 1, Y.J. Jung 1
The Catholic University of Korea, Daejeon St. Mary's Hospital - Daejeon (Korea, Republic of)
- LP13** **Predictive model incorporating polygenic risk score for Alzheimer's Disease predicts MMSE decline in APOE4 carriers and noncarriers**
A. Moore 1, J. Cara 1, A. Torkamani 2, L. Schneider 3, J. Collens 1
1Vivid Genomics - San Diego (United States), 2Scripps Research Translational Institute - La Jolla (United States), 3Keck School Of Medicine Of The University Of Southern California - Los Angeles (United States)

THEME 8

Health economics and clinical trials

- P69** **Mortality Risk and Use of Long-Term Custodial Care for Patients With Dementia and Psychosis Versus Patients With Dementia Only: A Longitudinal, Matched Cohort Analysis of Medicare Claims Data**
N. Rashid 1, J. Wetmore 2, 3, M. Irfan 4, V. Ablner 1
1ACADIA Pharmaceuticals, Inc. - San Diego, CA (United States), 2Chronic Disease Research Group - Minneapolis, MN (United States), 3Hennepin County Medical Center - Minneapolis, MN (United States), 4University Of Minnesota And Veterans Affairs Medical Center - Minneapolis, MN (United States)
- P70** **Estimating progression rates across the spectrum of Alzheimer's disease for amyloid positive individuals using National Alzheimer's Coordinating Center data**
M. Potashman 1, M. Buessing 2, M. Levitchi Benea 1, J. Cummings 3, 4, S. Borson 5, P. Pemberton Ross 6, A.J. Epstein 2
1 Biogen - Cambridge, MA (United States), 2 Medicus Economics - Boston, MA (United States), 3 Chambers-Grundy Center For Transformative Neuroscience Unlv - Las Vegas, NV(United States), 4 Cleveland Clinic Lou Ruvo Center for Brain Health - Las Vegas, NV(United States), 5 University Of Washington - Seattle, WA (United States), 6 Biogen - Baar (Switzerland)
- P71** **Comparative efficacy, safety, tolerability, and effectiveness of antipsychotics in the treatment of dementia related psychosis (DRP): A systematic literature review**
I. Yunusa 1, N. Rashid 2, S. Chaugule 1, V. Ablner 2, K. Rajagopalan 1
1 An-Lt-Iks, Inc - Boston, MA (United States), 2 Acadia Pharmaceuticals, Inc - San Diego, CA (United States)
- P72** **Caregiver perspectives on the burden and impact of agitation in caring for loved ones with Dementia/Alzheimer's disease: A collaboration with UsAgainstAlzheimer's A-LIST®**
M. Sanon Aigbogun 1, M. Cloutier 2, E. Serra 2, T. Frangiosa 3, V. Biggar 3, R. Baker 1, M. Michael 4, H. Gandhi 1, M. Gauthier-Loiselle 2
1 Otsuka Pharmaceutical Development & Commercialization, Inc. - Princeton, NJ (United States), 2 Analysis Group, Inc. - Montreal (Canada), 3 Usagainst Alzheimer's - Washington, DC (United States), 4 Otsuka America Pharmaceutical, Inc. - Princeton, NJ (United States)

● POSTER PRESENTATIONS

THEME 9

Epidemiology and clinical trials

P74 Comparing Alzheimer's disease (AD) progression in Alzheimer's Disease Neuroimaging Institute (ADNI) subjects with mild cognitive impairment (MCI) to progression observed in the SCarlet RoAD clinical trial

S. Yiu 1, F. Model 2, L. Butler 2, C. Gower-Page 1, X. Teitsma 2, P. Delmar 2
1 Roche Products Limited - Welwyn Garden City (United Kingdom), 2 F. Hoffmann-La Roche Ltd - Basel (Switzerland)

LP14 Alzheimer's Association International Cohort Study of Chronic Neuropsychiatric Sequelae of SARS-CoV-2 (CNS-SARS-CoV-2)

G. De Erausquin 1, H.M. Snyder 2, M.C. Carrillo 2, A. Hosseini 3, T.S. Brugha 3, S. Seshadri 4, A.A. Cns Sars-Cov-2 Consortium 5
1The Glenn Biggs Institute For Alzheimer's And Neurodegenerative Diseases, Uthsa (United States), 2Alzheimer's Association - Chicago (United States), 3University Of Leicester - Leicester (United Kingdom), 4The Glenn Biggs Institute For Alzheimer's And Neurodegenerative Diseases, Uthsa - San Antonio (United States), 5On Behalf Of The Alz Cns Sars-Cov-2 Consortium - Chicago (United States)

THEME 11

New therapies and clinical trials

P75 Impact of pimavanserin treatment on motor function in patients with neurodegenerative disease: results from 3 clinical studies

D. Weintraub 1, E.P. Foff 2, C. Ballard 3, B. Mcevoy 2, B. Coate 2, G. Demos 2, A. Berrio 2, B. Abbs 2, J.M. Youakim 2, S. Stankovic 2
1Departments Of Psychiatry And Neurology, Perelman School Of Medicine At The University Of Pennsylvania - Philadelphia (United States), 2ACADIA Pharmaceuticals, Inc - Princeton (United States), 3University Of Exeter Medical School, Exeter - Exeter (United Kingdom)

P76 A phase 2a, open-label multicenter study to evaluate the safety and tolerability of repeated intrathecal administration of NurOwn® (autologous mesenchymal stem cells secreting neurotrophic factors) in patients with prodromal to mild Alzheimer's Disease

B. Dubois 1, R. Kern 2, S. Ward 2, S. Lindborg 2, C. Lebovits 2, P. Scheltens 3
1Salpêtrière University Hospital - Paris (France), 2Brainstorm Cell Therapeutics - New York (United States), 3Amsterdam Umc - Amsterdam (Netherlands)

P77 The epigenetic BET protein inhibitor apabetalone counters brain endothelial activation and monocyte adhesion

E. Kulikowski 1, S. Wasiak 1, L. Fu 1, E. Daze 1, D. Gilham 1, B. Rakai 1, S. Stotz 1, L. Tsujikawa 1, C. Sarsons 1, D. Studer 2, K. Rinker 2, R. Jahagirdar 1, N. Wong 1, M. Sweeney 1, J. Johansson 1
1 Resverlogix Corp - Calgary (Canada), 2 University Of Calgary - Calgary (Canada)

P78 ACD856, a novel cognitive enhancer targeting neurotrophin signaling for the treatment of Alzheimer's Disease

P. Forsell 1, G. Nordvall 1, M. Halldin 1, M. Dahlström 1, N. Madjid 1, M. Rother 1, A. Van Es Johansson 1, J. Lundkvist 1, M. Eriksson 2, 3, M. Jönsson 1, B. Winblad 2, 3, J. Sandin 1
1 Alzecure Pharma Ab - Huddinge (Sweden), 2 Dept of Neurobiology, Care Sciences And Society, Karolinska Institutet - Stockholm (Sweden), 3 Dept Geriatric Medicine, Karolinska University Hospital - Huddinge (Sweden)

P79 Therapeutic efficacy of a small molecule inhibitor targeting tau self-association in mouse models of tauopathy

J. Moe 1, P. Lopez 1, H. Jimenez-Bravar 2, L. Adrien 2, J. Eun 2, A. Wolin 2, J. Koppel 2, P. Davies 2, E. Davidowitz 1
1Oligomerix, Inc. - White Plains (United States), 2The Litwin-Zucker Research Center For The Study Of Alzheimer's Disease, The Feinstein Institute For Medical Research, Northwell Health - Manhasset (United States)

P80 Development of a Dual A β -Tau Vaccine for the Prevention and Treatment of Alzheimer's Disease

R. Barbour 1, F. Bard 1, A. Elmaarouf 1, H. Prill 1, K. Thomas 1, G. Kinney 1, W. Zago 1
Prothena Biosciences Inc - South San Francisco, CA (United States)

P81 Novel Amyloid Beta Monoclonal Antibodies with Superior Binding Properties: Potential for More Convenient Dosing and Greater Patient Access in Alzheimer's Disease

M. Skov 1, R. Barbour 1, P. Dolan 1, A. Elmaarouf 1, E. Goldbach 1, M. Holden 1, L. Li 1, T. Nijjar 1, H. Prill 1, J. Salmans 1, K. Thomas 1, S. Tam 1, C. Tourino 1, F. Bard 1, G. Kinney 1, Z. Wagner 1
Prothena Biosciences Inc - South San Francisco, CA (United States)

P82 Gamma-secretase modulators show selectivity for gamma-secretase-mediated amyloid precursor protein intramembrane processing

J. Lundkvist 1, 2, T. Weber 3, 2, J. Wanngren 2, H. Kvarnström 4, 5, P. Larssen 2, 6, D. Wu 2, 7, D. Oliveira 2, J. Sandin 1, 2, H. Zetterberg 4, 5, 8, K. Blennow 4, 5, G. Nordvall 1, 2, B. Winblad 2, E. Portelius 4, 5, H. Karlström 2
1 Alzecure Pharma - Stockholm (Sweden), 2 Department Of Neurobiology, Care And Society, Karolinska Institutet - Solna (Sweden), 3 Aesculap Ag - Tuttlingen (Germany), 4 Department Of Psychiatry And Neurochemistry, Institute Of Neuroscience And Physiology, The Sahlgrenska Academy At The University Of Gothenburg - Gothenburg (Sweden), 5 Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital - Mölndal (Sweden), 6 Mabtech AB - Stockholm (Sweden), 7 Department Of Obstetrics And Gynecology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu - Nanjing (China), 8 Department of Neurodegenerative Disease, UCL Institute of Neurology - London (United Kingdom)

POSTER PRESENTATIONS

- P83** **Predicting Response to Virtual Reality Therapy for Treatment of BPSD in Acute-care Settings**
L. Appel 1, B. Chen 2, E. Kisonas 3, E. Appel 3, J. Rosenberg 3, C. Smith 3
1 York University - Toronto (Canada), 2 University Of Toronto - Toronto (Canada), 3 Uhn - Toronto (Canada)
- P84** **Administering Virtual Reality Therapy to Manage Behavioural and Psychological Symptoms in Patients with Dementia Admitted to an Acute-care Hospital: Results of a Pilot Study**
L. Appel 1, E. Kisonas 2, E. Appel 2, D. Bartlett 3, J. Klein 1, J. Rosenberg 4, C. Smith 4
1 York University - Toronto (Canada), 2 Uhn - Toronto (Canada), 3 York U - Toronto (Canada), 4 Mgh - Toronto (Canada)
- P85** **Introducing Virtual Reality therapy for inpatients with dementia admitted to an acute-care hospital: Learnings from a pilot to pave the way to a randomized controlled trial**
L. Appel 1, E. Kisonas 2, E. Appel 2, J. Klein 3, D. Bartlett 3, J. Rosenberg 4, C. Smith 4
1 York University - Toronto (Canada), 2 Uhn - Toronto (Canada), 3 York U - Toronto (Canada), 4 Mgh - Toronto (Canada)
- P86** **Non-invasive gamma sensory stimulation for the treatment of Alzheimer's disease: interim safety and feasibility from multiple prospective clinical studies evaluating long-term, home use**
Z. Malchano 1, E. Hempel 1, A. Boasso 1, N. Myrthil 1, K. Martin 1, N. Strozewski 1, T. Travers 1, K. Kwan 1, C. Cotter 1, M. Williams 1, A. Cimenser 1, M. Hajos 1
Cognito Therapeutics - Cambridge, MA (United States)

THEME 12

Proof of concept/translational research in AD

- P88** **Regular Running can Prevent AD by Enhancing Hippocampal Proliferation**
X. Bo 1, Z. Xianliang 1
School of Physical Education & Health Care, East China Normal University - Shanghai (China)
- P89** **Effects of THN201, a combination of donepezil and low dose mefloquine, on cognition and quantitative EEG in healthy subjects during a scopolamine challenge**
T. Dondaine 1, D. Deplanque 1, O. Blin 2, C. Cracowski 3, P.O. Girodet 4, G. Pickering 5, C. Thalams 6, F. Mouthon 7, M. Charvériat 7, W. Rein 7, R. Bordet 1
1Lille University - Lille (France), 2Marseille University - Marseille (France), 3Grenoble University - Grenoble (France), 4Bordeaux University - Bordeaux (France), 5Clermont-Ferrand University - Clermont-Ferrand (France), 6Toulouse University - Toulouse (France), 7Theranexus - Fontenay Aux Roses (France)
- P90** **Reduced non-fibrillar A β species in a patient treated with low doses of BACE1 inhibitor**
M. Querol-Vilaseca 1, 2, S. Sirisi 1, 2, L. Molina-Porcel 3, 4, B. Molina 1, 2, J. Pegueroles 1, 2, P. Ferrer-Raventós 1, 2, R. Nuñez-Llaves 1, 2, R. Blesa 1, 2, O. Belbin 1, 2, J. Fortea 1, 2, R. Sánchez-Valle 3, 4, A. Lleó 1, 2
1Memory Unit, Department of Neurology, Institut D'investigacions Biomèdiques Sant Pau-Hospital De Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. - Barcelona (Spain), 2Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain. - Madrid (Spain), 3Neurological Tissue Bank Of The Biobanc-Hospital Clínic-Idibaps, Barcelona Spain. - Barcelona (Spain), 4Alzheimer's disease and other cognitive disorders unit. Neurology Service, Hospital Clínic de Barcelona-IDIBAPS, Barcelona Spain - Barcelona (Spain)
- P91** **Independent validation of EuroPOND Alzheimer's disease staging model on real-world clinical data**
M.M.J. Wittens 1, D.M. Sima 2, A. Brys 2, E. De Roeck 1, H. Struyfs 1, E. Niemantsverdriet 1, M. Bellio 3, N. Oxtoby 3, D. Alexander 3, A. Ribbens 2, S. Engelborghs 1, 4
1Dep. Of Biomedical Sciences, Institute Born-Bunge, University Of Antwerp - Antwerpen (Belgium), 2Icometrix - Leuven (Belgium), 3Centre For Medical Image Computing, Department Of Computer Science, U C L - London (United Kingdom), 4Dep. of Neurology and Center for Neurosciences, UZ Brussel and Vrije Universiteit Brussel (VUB) - Jette (Belgium)
- P93** **Quantitative Systems Pharmacology model of tau spreading in AD to enable the development of anti-tau therapies**
L. Wille 1, J. Grant 1, S. Iadevaia 2, H. Abdul 1, K. Madras 1, A. Simen 2, A.J. Schwarz 2, M. Quinton 2, H. Faessel 2, F. Hua 1, J. Appgar 1, J. Burke 1, M. Vakilynejad 2
1Applied Biomath - Concord, MA (United States), 2Takeda - Cambridge, MA (United States)
- P94** **Investigating the Global Proteomic Impact and Translational Implications of Tolfenamic Acid Treatment**
J. Hill 1, N. Zawia 1, 2, 3
1Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island - Kingston, RI (United States), 2Interdisciplinary Neuroscience Program, University of Rhode Island, - Kingston, RI (United States), 3George and Anne Ryan Institute for Neuroscience, University of Rhode Island - Kingston, RI (United States)

POSTER PRESENTATIONS

- P95** **The lack of c-Abl improves behavioral performance in an animal model of Alzheimer's disease**
A. Alvarez 1, R. León 1, C. Riquelme 1, S. Zanlungo 2, A. Dulcey 3, J. Marugan 3
1Cell Signaling Laboratory, Department of Cell and Molecular Biology, Biological Sciences Faculty, Care-Uc, P. Universidad Catolica De Chile - Santiago (Chile), 2Gastroenterology Department, School of Medicine, P. Universidad Catolica De Chile - Santiago (Chile), 3Ncats-NIH Chemical Genomic Center - Bethesda, MD (United States)
- LP16** **Peripheral inflammation, cognitive impairment and AD-related hippocampal neurodegeneration in prodromal AD patients**
M. Marizzoni 1, C. Chevalier 2, N. Lopizzo 1, D. Albani 3, G. Forloni 3, J. Jovicich 4, A. Cattaneo 1, G. Frisoni 2
1Ircs Istituto Centro San Giovanni Di Dio Fatebenefratelli - Brescia (Italy), 2University Hospitals And University Of Geneva - Geneva (Switzerland), 3Ircs Istituto Di Ricerche Farmacologiche "mario Negri" - Milano (Italy), 4Center For Mind/brain Sciences - Trento (Italy)
- LP17** **CS6253 ABCA1 agonist treatment in cynomolgus monkeys reduces cerebrospinal fluid concentrations of A β 42, A β 40, APP and AP2B1 in dose-response manner**
J.O. Johansson 1, H.N. Yassine 2, D.M. Michaelson 3, J.E.G. Johansson 4, H. Zetterberg 5, B. Winblad 6, J.L. Cummings 7
1Artery Therapeutics, Inc. - San Ramon, Ca (United States), 2Usc - Los Angeles (United States), 3Tel Aviv University - Tel Aviv (Israel), 4Artery Therapeutics, Inc. - San Ramon (United States), 5U Of Gothenburg - Gothenburg (Sweden), 6Karolinska Institutet - Stockholm (Sweden), 7Unlv - Las Vegas (United States)

THEME 13

Digital health/E-trials

- P96** **Evaluation of speech-based digital biomarkers for Alzheimer's disease**
J. Robin 1, L. Kaufman 1, W. Simpson 1, 2
1Winterlight Labs - Toronto (Canada), 2McMaster University - Hamilton (Canada)
- P97** **Developing and assessing a digitally supported care management programme for caregivers of people with dementia: A cluster-randomised controlled trial (GAIN)**
O.A. Klein 1, J.R. Thryian 2, M. Boekholt 2, D. Afrin 2, C. Dornquast 2, M. Lindner 2, B. Michalowsky 2, I. Zwingmann 3, A. Dreier-Wolfgramm 4, S. Teipel 1, W. Hoffmann 2, I. Kilimann 1
1German Center For Neurodegenerative Diseases - Rostock (Germany), 2German Center For Neurodegenerative Diseases - Greifswald (Germany), 3European University Of Applied Sciences - Rostock (Germany), 4Hamburg University Of Applied Sciences - Hamburg (Germany)
- P98** **Validating virtual tools for remote sampling of neurological function: comparing task-driven EEG in the lab and in the home**
B. Murphy 1, F. Barbey 1, A. Buick 2, J. Dyer 1, H. Nolan 1
1Brainwavebank Ltd. - Dublin (Ireland), 2Brainwavebank Ltd. - Belfast (United Kingdom)
- P99** **Measurement of Alzheimer's Disease symptomatology using remote smartphone-based assessment of visual and auditory behavior**
A. Abbas 1, A. Paley 1, I. Galatzer-Levy 1
Aicure - New York (United States)
- P100** **Automated administration of Serial Subtraction in a remote data collection context: novel timing features related to task difficulty and participant demographics**
N. Taptiklis 1, B. Jennifer 1, 2, F. Francesca 1, 2
1Cambridge Cognition - Cambridge (United Kingdom), 2Dept. Psychiatry, University of Cambridge - Cambridge (United Kingdom)
- LP18** **Feasibility, acceptability and effects on clinical outcomes of a web-based multidomain lifestyle intervention in older adults: the eMIND randomized controlled trial**
P. De Souto Barreto 1, K. Pothier 2, G. Soriano 1, M. Lussier 3, L. Bherer 3, S. Guyonnet 1, A. Piau 1, P.J. Ousset 1, B. Vellas 1
1Gerontopole Of Toulouse - Toulouse (France), 2University Of Tours - Tours (France), 3Université De Montréal - Montreal (Canada)

THEME 14

Telemedicine and AD clinical trials

- P101** **Reinventing Alzheimer's Disease Prescreening: The Global Alzheimer's Platform Foundation® (GAP) Remote Recruitment and Prescreening Program**
L. Zisko 1, C. Cordell 1, J. Smith 1, J. Trotter 1, L. Thurman 1, J. Sipchen 1
Global Alzheimer's Platform Foundation (gap) - Washington (United States)